Moderna Shares Gain 1.54% Ahead of November Earnings Report

Moderna shares advanced during the October 21, 2026, trading session, outperforming major US stock indexes as investors assessed the biotechnology company's recent performance and upcoming financial results. The stock closed at $245.81, supported by a 1.54% daily gain, according to financial market data published by Yahoo Finance.

The increase exceeded the S&P 500's 0.58% advance, the Dow's 0.69% rise, and the Nasdaq's 1.05% gain. Moderna's shares had also climbed 32.6% over the preceding month, compared with a 3.5% increase in the medical sector and a 0.97% gain for the S&P 500, according to Yahoo Finance.

Investors are preparing for Moderna's next earnings release, scheduled for November 6, 2026. Consensus estimates cited by Yahoo Finance project quarterly earnings of negative $1.37 per share and revenue of $888.78 million, representing a 12.52% decline in revenue from the corresponding quarter a year earlier.

For the full year, Zacks Consensus Estimates project a loss of $8.52 per share and revenue of $2.1 billion. The estimates indicate a 17.36% change in annual earnings and an 8.27% increase in revenue compared with the previous year, according to the financial report.

Analyst estimate revisions remain another factor investors monitor when evaluating the company's near-term outlook. Yahoo Finance's report notes that changes in earnings forecasts can reflect evolving expectations about business performance and profitability, although the article does not identify specific revisions to Moderna's estimates.

Moderna operates in the medical biotechnology and genetics industry, which falls within the broader medical sector. The industry held a Zacks Industry Rank of 101, placing it among the top 42% of more than 250 industries tracked by the ranking system, according to the report.

A separate October 22, 2026, report from Investors.com highlighted volatility surrounding Moderna after a report concerning allegedly leaked cancer vaccine data. Its headline described a 20% decline in the stock, while the same report discussed Arcus Biosciences and its kidney cancer treatment results, which drew investor attention and prompted a reversal in the company's share movement.

The Investors.com report also stated that Arcus Biosciences promoted results for its kidney cancer treatment on October 20, 2026, describing the treatment as a competitor to Merck's offering. Arcus shares rose after reversing an earlier premarket decline, according to the report.

The two reports present different snapshots of biotechnology market activity. Yahoo Finance documented Moderna's positive closing performance on October 21, while Investors.com highlighted reported volatility linked to cancer vaccine data on October 22. Moderna's next scheduled earnings release remains November 6, 2026.